Translation and Cultural Adaptation of the Pain Impact Questionnaire (PIQ-6) Among Chronic Pain Patients in Japan
Moderator
Ayumi Morishita, IQVIA Solutions Japan, Minato-ku, Japan
Speakers
Anzu Yakushiji, IQVIA Solutions Japan K,K., Tokyo, Japan; Louis Patrick Watanabe; Sara Higa; Kanoko Watanabe; Misaki Sasanami; Sven Demiya, MBA, MSc, PhD, IQVIA, Minato-ku, Japan; Koki Idehara, PhD, IQVIA Solutions Japan G. K, Tokyo, Japan
OBJECTIVES: The Pain Impact Questionnaire (PIQ-6) is a 6-item measure to assess the severity of pain and its impact on the patient’s quality of life. The aim of this study was to develop the Japanese version of the PIQ-6 and psychometrically validate the measure for Japanese patients with chronic pain conditions. Here we will report the results from the initial phase of the study where we conducted the translation and cognitive debriefing interviews for the development of the Japanese PIQ-6.
METHODS: The Japanese version of the PIQ-6 was developed in accordance with the ISPOR task force guidelines. Forward and back translations were conducted to develop the preliminary version of the Japanese PIQ-6. Modifications were made to the preliminary version for cultural adaptation based on cognitive debriefing interviews with a sample of chronic pain patients. Chronic pain was defined as pain persisting or recurring for longer than 3 months, as defined by ICD-11. Participants with chronic pain conditions outlined in the 2021 Japanese guidelines for the management of chronic pain were recruited. Relevant conditions included lower back pain, knee osteoarthritis, migraine, postherpetic neuralgia, trigeminal neuralgia, and rheumatism.
RESULTS: Thirty Japanese patients with a chronic pain condition were included in the cognitive debriefing interviews. The cognitive debriefing interviews identified some issues with the preliminary version of the Japanese PIQ-6. These were modified accordingly for clarity and cultural adaptation.
CONCLUSIONS: In the initial phase, a culturally adapted version of the Japanese PIQ-6 was developed through forward and back translations and cognitive debriefing interviews with Japanese patients with chronic pain conditions. In the subsequent phase of the study, the psychometric properties of the culturally adapted Japanese version of the PIQ-6 will be assessed using a larger sample of Japanese patients with chronic pain conditions.
METHODS: The Japanese version of the PIQ-6 was developed in accordance with the ISPOR task force guidelines. Forward and back translations were conducted to develop the preliminary version of the Japanese PIQ-6. Modifications were made to the preliminary version for cultural adaptation based on cognitive debriefing interviews with a sample of chronic pain patients. Chronic pain was defined as pain persisting or recurring for longer than 3 months, as defined by ICD-11. Participants with chronic pain conditions outlined in the 2021 Japanese guidelines for the management of chronic pain were recruited. Relevant conditions included lower back pain, knee osteoarthritis, migraine, postherpetic neuralgia, trigeminal neuralgia, and rheumatism.
RESULTS: Thirty Japanese patients with a chronic pain condition were included in the cognitive debriefing interviews. The cognitive debriefing interviews identified some issues with the preliminary version of the Japanese PIQ-6. These were modified accordingly for clarity and cultural adaptation.
CONCLUSIONS: In the initial phase, a culturally adapted version of the Japanese PIQ-6 was developed through forward and back translations and cognitive debriefing interviews with Japanese patients with chronic pain conditions. In the subsequent phase of the study, the psychometric properties of the culturally adapted Japanese version of the PIQ-6 will be assessed using a larger sample of Japanese patients with chronic pain conditions.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PCR56
Topic
Patient-Centered Research
Topic Subcategory
Instrument Development, Validation, & Translation, Patient-reported Outcomes & Quality of Life Outcomes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)